🇺🇸 FDA
Patent

US 11459340

Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors

granted A61KA61K31/5383A61P

Quick answer

US patent 11459340 (Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors) held by NIKANG THERAPEUTICS, INC. expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
NIKANG THERAPEUTICS, INC.
Grant date
Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/5383, A61P, A61P35/00